Myriad Genetics
MYGN
223 hedge funds and large institutions have $1.7B invested in Myriad Genetics in 2016 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 91 increasing their positions, 72 reducing their positions, and 57 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 72
12% less funds holding
Funds holding: 252 → 223 (-29)
32% less capital invested
Capital invested by funds: $2.5B → $1.7B (-$808M)
32% less call options, than puts
Call options by funds: $5.41M | Put options by funds: $7.99M
44% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 57
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$59.2M |
| 2 |
Renaissance Technologies
New York
|
+$40.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.4M |
| 4 |
Neuberger Berman Group
New York
|
+$29.8M |
| 5 |
NTC
North Tide Capital
Boston,
Massachusetts
|
+$25.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
-$98.4M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$77.6M |
| 3 |
SCM
Scopia Capital Management
New York
|
-$25.2M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$22.1M |
| 5 |
RA
Royce & Associates
New York
|
-$21.5M |
MYGN Hedge Fund Activity: Q3 2016 in Review
223 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q3 2016, worth a combined $1.7B — down 32% from $2.5B a quarter earlier.
Sellers outnumbered buyers: 57 funds closed out of MYGN and 32 opened new positions — a net loss of 25 holders — while 72 trimmed existing stakes and 91 added.
The largest buyer was Acadian Asset Management, adding an estimated $59.2M. The largest seller was Iridian Asset Management, exiting entirely with an estimated $98.4M sold.
- 223 institutional investors held Myriad Genetics (MYGN) as of Q3 2016, down from 252 in Q2 2016.
- Funds reported $1.7B of Myriad Genetics stock for Q3 2016, down 32% quarter-over-quarter.
- 32 funds opened new Myriad Genetics positions in Q3 2016 and 57 closed out, a net change of -25 holders.
- The largest Myriad Genetics buyer in Q3 2016 was Acadian Asset Management, an estimated $59.2M added.
- The largest Myriad Genetics seller in Q3 2016 was Iridian Asset Management, an estimated $98.4M sold.
Based on aggregated 13F filings for Q3 2016.